Biotechnology firm Ocugen has announced significant progress across its pipeline targeting inherited retinal diseases, alongside its latest financial results. The company confirmed the completion of patient enrollment for a pivotal trial and provided a funding update to support its operations.
Financial Position and Capital Raise
For the full year 2025, Ocugen reported a net loss of $67.8 million. Revenue for the period stood at $4.4 million, stemming from a collaboration agreement. The net loss per share for the fourth quarter of 2025 was $0.06, aligning with analyst projections.
The company concluded 2025 with $18.9 million in cash and equivalents. To bolster its balance sheet, Ocugen executed a direct stock offering in January 2026, generating gross proceeds of $22.5 million. Management stated these funds are expected to be sufficient to finance operations through the end of the fourth quarter of 2026. The company’s shares were last quoted at €1.51, reflecting a year-to-date gain exceeding 158%.
Pipeline Advancements Take Center Stage
A major clinical milestone was reached for OCU400, Ocugen’s lead candidate for Retinitis pigmentosa. The company has fully enrolled its Phase 3 “liMeliGhT” trial. The regulatory pathway involves initiating a rolling Biologics License Application (BLA) submission in the third quarter of 2026. Initial topline data from the study is anticipated in the first quarter of 2027.
Should investors sell immediately? Or is it worth buying Ocugen?
Progress was also reported on other assets. Patient recruitment is nearing completion for the Phase 2/3 trial of OCU410ST, which is being developed for Stargardt disease. Interim results from this study are expected in Q3 2026. Furthermore, complete data from the Phase 2 trial for OCU410 in geographic atrophy is slated for release this month, March 2026.
Corporate and Legal Proceedings
Beyond clinical and financial updates, the company disclosed an ongoing legal process in Delaware. The proceeding seeks to validate a prior amendment to the corporate charter concerning authorized share capital. A court hearing on the matter is scheduled for May 2026.
For investors, the next critical catalyst is viewed as the commencement of the BLA submission process for OCU400 in the latter half of 2026.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from March 6 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 6.
Ocugen: Buy or sell? Read more here...
